Plasma pTau217 may detect initial buildup of AD-related brain changes before they can be detected by current ‘gold standard’ ...
NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid ...
Combined and cumulative physical and social environmental exposure may be more closely linked to brain aging than a clinical ...
NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta ...
Studies have confirmed the existence of neurogenesis in the adult human brain, but whether newborn neurons bolster cognitive abilities remains controversial. In the February 25 Nature, scientists led ...
Scientists have identified hundreds of genes that may increase the risk of developing Alzheimer’s disease but the roles these genes play in the brain are poorly understood. This lack of understanding ...
For over a century, Alzheimer's disease (AD) has been considered irreversible. Consequently, research has focused on disease prevention or slowing, rather than recovery. Despite billions of dollars ...
NeuraLight at AD/PD 2026: Revealing Next-Generation Brain-Function Biomarker Readouts Powering a First-of-its-Kind Neuroprotection Signal in Drug Trials Breakthrough neuroprogression biomarker, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results